LesothoTuberculosis profile
Population  2014 2.1 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.4 (0.81–2.1) 64 (38–97)
Mortality (HIV+TB only) 4.9 (3.4–6.6) 231 (160–315)
Prevalence  (includes HIV+TB) 14 (7.8–22) 671 (369–1 063)
Incidence  (includes HIV+TB) 18 (13–24) 852 (612–1 131)
Incidence (HIV+TB only) 12 (8.5–16) 578 (405–781)
         
Case detection, all forms (%) 49 (37–69)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 3.2 (2.2–4.1) 7.3 (4.2–10)
MDR-TB cases among notified pulmonary
TB cases
220 (150–280) 110 (66–160)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 2 619   519
Pulmonary, clinically diagnosed 4 312   27
Extrapulmonary 1 363   0
       
Total new and relapse 8 840    
Previously treated, excluding relapses 1 016    
Total cases notified 9 856    
Among 8 840 new and relapse cases:
368 (4%) cases aged under 15 years; male:female ratio: 1.3
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 461 (18%) 79 (5%) 540
Laboratory-confirmed RR-/MDR-TB cases     148
Patients started on MDR-TB treatment ***     152
TB/HIV 2014 Number (%)
TB patients with known HIV status 9 145 (93)
HIV-positive TB patients 6 600 (72)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 6 600 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 4 866 (74)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (70) 9 119
Previously treated cases registered in 2013 (62) 1 619
HIV-positive TB cases, all types, registered in 2013 (66) 7 683
RR-/MDR-TB cases started on second-line treatment in 2012 (64) 146
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 0.9
Culture (per 5 million population) 2.4
Drug susceptibility testing (per 5 million population) 2.4
Sites performing Xpert MTB/RIF 17
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 5.9
% Funded domestically 14%
% Funded internationally 86%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-07-24 Data: www.who.int/tb/data